Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Tango Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Tango Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Tango Therapeutics Receivables Turnover Related Terms
Tango Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Tango Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNGX vs LEGN, CAI, EWTX: Receivables Turnover Comparison
For the Biotechnology subindustry, Tango Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tango Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tango Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Tango Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tango Therapeutics (TNGX) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tango Therapeutics and its competitors. According to the industry distribution chart, Tango Therapeutics ranks #999999 out of 842 companies in the Biotechnology industry.
Is Tango Therapeutics' Receivables Turnover too high?
Tango Therapeutics' current Receivables Turnover is 0.00. Based on the distribution chart, Tango Therapeutics ranks #999999 out of 842 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tango Therapeutics has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tango Therapeutics' Receivables Turnover compare to LEGN and CAI?
According to the Biotechnology industry distribution chart, Tango Therapeutics ranks #999999 out of 842 companies for Receivables Turnover. This places Tango Therapeutics in the lower half of its industry. The industry median Receivables Turnover is 5.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Tango Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tango Therapeutics's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tango Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Tango Therapeutics (TNGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.92, compared to a current price of $26.94 — trading 171.6% above its estimated fair value. The current Receivables Turnover is 0.00. Tango Therapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Tango Therapeutics (TNGX), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tango Therapeutics (TNGX) Overvalued in 2026?
Based on GuruFocus' analysis, Tango Therapeutics stock appears to be overvalued.
The current stock price of $26.94 is trading 171.6% above its estimated GF Value™ of $9.92.
GuruFocus considers Tango Therapeutics to be Significantly Overvalued.
Key valuation signals for TNGX:
Receivables Turnover: 0.00
GF Value™: $9.92 vs. price of $26.94 (171.6% above fair value)
No single metric tells the full story. See the TNGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
54GF Score
Get the complete analysis for TNGX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNGX has been successfully added to your 
